Clear cell papillary renal cell carcinoma (CCPRCC) is a recently recognised neoplasm with a broad spectrum of morphological characteristics, thus representing a challenging differential diagnosis, especially with the low malignant potential multicystic renal cell neoplasms and clear cell renal cell carcinoma. We selected 14 cases of CCPRCC with a wide spectrum of morphological features diagnosed on morphology and CK7 immunoreactivity and analysed them using a panel of immunohistochemical markers, focusing on 34bE12 and related CKs 1,5,10 and 14 and several molecular analyses such as fluorescence in situ hybridisation (FISH), array comparative genomic hybridisation (aCGH), VHL methylation, VHL and TCEB1 sequencing and multiplex ligation-dependent probe amplification (MLPA). Twelve of 13 (92%) CCPRCC tumours were positive for 34bE12. One tumour without 3p alteration by FISH revealed VHL mutation and 3p deletion at aCGH; thus, it was re-classified as clear cell RCC. We concluded that: (1) immunohistochemical expression of CK7 is necessary for diagnostic purposes, but may not be sufficient to identify CCPRCC, while 34bE12, in part due to the presence of CK14 antigen expression, can be extremely useful for the recognition of this tumour; and (2) further molecular analysis of chromosome 3p should be considered to support of CCPRCC diagnosis, when FISH analysis does not evidence the common loss of chromosome 3p.
INTRODUCTION
Clear cell papillary renal cell carcinoma (CCPRCC) is a recently recognised neoplasm that occurs in patients with end-stage renal disease and acquired cystic kidney disease as well as in otherwise normal kidneys. 1, 2 It is estimated that these tumours constitute up to 3% of adult renal cell carcinomas (RCCs) 3 and are the fourth most common histological type of RCC. 4 These tumours were originally described as being multicystic, with a prominent papillary architecture. Initial reports indicated that these tumours were composed entirely of clear cells with nuclei usually arranged in a linear fashion away from the basement membrane having a superficial resemblance to the cells of early secretory endometrium. 1 Moreover, the neoplastic cells were initially reported to constantly and diffusely express cytokeratin (CK) 7 and to be predominantly negative for alpha-methylacylCoA racemase (P504S) and CD10. A characteristic genetic alteration has not yet been identified for CCPRCC; 2, [5] [6] [7] [8] however, the majority of tumours do not show the gains of chromosome 7 and 17 2, 3, 5, 7 characteristic of papillary RCC. 8 They similarly lack chromosome 3p deletion and mutation or methylation of the VHL gene, which characterises clear cell RCC. Rohan et al. reported a series of nine tumours showing co-expression of CAIX, HIF-1alpha, and GLUT-1 in the absence of VHL gene alterations, which suggests activation of the HIF pathway by non-VHL-dependent mechanisms. 5 In this study the authors concluded that these tumours were easily separable from papillary RCC with clear cell changes and clear cell RCC with focal papillary architecture, based on morphological features. Moreover, they noted that in only rare instances was the support of immunohistochemical staining an absolute requirement for differentiating between these two tumour types. 5 Williamson et al. have highlighted examples of CCPRCC in which the papillary component is relatively inconspicuous, with predominance of a cystic or prominent solid or dense tubular component. They also showed 59% of these tumours to express CD10, especially in the cystic areas and thus to some degree mimic both low malignant potential multicystic renal cell neoplasms and conventional clear cell RCC. 9 In addition to these findings, CCPRCC-like tumours have been reported in patients with or without Von Hippel-Lindau disease, underlining the difficulties in distinguishing CCPRCC from conventional clear cell RCC. 10, 11 More recently, Aron et al. and Deml et al. have reported a few cases of CCPRCC notably with VHL mutation 12, 13 and Hakimi et al. observed TCEB1 mutation in a series of tumours with morphological and immunohistochemical overlap with CCPRCC. 14 In this study we performed a thorough immunophenotypical analysis of a total of 14 CCPRCC cases, paying special attention to the expression of 34bE12 and CK14. We also evaluated the expression of these markers in a set of tissue microarrays (TMAs) containing 150 cases of conventional clear cell RCCs. Moreover, we undertook a detailed genetic analysis of a subset of five cases with microscopic features representative of the morphological spectrum described so far in the literature in CCPRCC.
MATERIALS AND METHODS

Tissue samples
A total of 14 cases of CCPRCC were accessioned from the archives of the Department of Pathology and Diagnostics, University and Hospital Trust of Verona and Anatomic Pathology, Pederzoli Hospital of Peschiera del Garda, Verona (diagnosed from 2003 to 2012). In these cases the diagnosis was based on the presence of specific morphological features previously described in these tumours, including papillary, branching tubular, tubulo-glandular and cystic patterns. For each case, 1-12 (on average 5) paraffin-embedded tissue blocks were available. Sections 3 mm thick were cut from tissue blocks and stained with haematoxylin and eosin (H&E). The diagnosis was reviewed independently by three urological pathologists (MB, SG, GM). TMAs containing 150 cases of clear cell RCC were also used for immunostain evaluation as comparison with CCPRCC.
Immunohistochemical analysis
The immunohistochemical profile of each tumour was investigated using a panel of antibodies that consisted of: CD10 (clone 56C6, 1:10 dilution; Novocastra, USA); cytokeratin 7 (clone OV-TL 12/30, 1:400 dilution; Biogenex, USA); cytokeratin 34bE12 (clone 34bE12, 1:40 dilution; Dako, USA); cytokeratin 1 (clone 34bB4, 1:50 dilution; Novocastra); cytokeratin 5 (clone XM26, 1:100 dilution; Novocastra); cytokeratin 10 (clone 2HP1, 1:50 dilution; Novocastra); cytokeratin 14 (clone LL002, 1:50 dilution; Biogenex); cytokeratin AE1/AE3 (clone AE1/AE3, 1:100; Dako); parvalbumin (clone P19, 1:400 dilution; Sigma Chemical Company, USA); CAIX (polyclonal, 1:100 dilution; Abcam, UK); SLC2A1 (GLUT1; polyclonal, rabbit, 1:100 dilution; Dako); alpha-methylacyl-CoA racemase (P504S; clone 13H7, 1:50 dilution; Dako); S100A1 (clone M01, 1:800 dilution; Abnova, Taiwan); desmin (clone D33, 1:500 dilution; Dako); a-smooth muscle actin (clone 1A4, 1:250 dilution; Dako); oestrogen receptor (1:20 dilution; Dako), progesterone receptor (clone PgR 636, 1:20 dilution; Dako); HMB45 (clone HMB45, 1:300 dilution; Dako) and cathepsin K (clone 3F9, 1:2000 dilution; Abcam). Immunoreactions were developed using a non-biotin, highly sensitive system (Envision peroxidase detection system; Dako) designed to prevent possible false-positive staining resulting from endogenous biotin present in the tissue.
Protein extraction and western blot analysis
Proteins were extracted from neoplastic tissues of six CCPRCCs and 10 clear cell RCCs. For each sample 20 serial 10 mm sections were collected into an Eppendorf tube, and 150 mL Cell Lysis Buffer (Cell Signaling Technology, USA) was added prior to heating at 100 C for 5 min. Samples were cooled for 5 min on ice, centrifuged at 140,000 × g for 15 min and supernatants were transferred to a new collection tube and stored at -20 C. Protein quantification was performed using the Bio-Rad protein assay kit (Bio-Rad, USA) according to the manufacturer's instructions. Twenty-five mg of extracted lysates was resolved in 10% polyacrylamide SDS-PAGE gel in a BioRad Mini Protean tetra cell system at 150V for 1 h. Electrophoresed proteins were transferred into a nitrocellulose membrane at 250 mA for 90 min. The membranes were blocked in TBST (Tris-Buffered saline and Tween 20) plus 5% non-fat dry milk for 1h at RT with constant shaking. Subsequently, the blots were incubated overnight, washed three times with TBST and incubated with the specific secondary anti-mouse or anti-rabbit peroxidase-conjugated anti-IgG antibody (diluted 1:2000; Cell Signaling, USA). After three washes with TBST, the immunoblots were visualised with ECLplus Western Blotting Substrate (Amersham/GE Healthcare Europe, Germany). Expression levels of each marker were quantified with ImageJ (https://imagej.nih.gov/ij/index.html) densitometric analysis.
Array comparative genomic hybridisation (aCGH) and data analysis
Microdissection of formalin fixed, paraffin embedded (FFPE) kidney tumours was performed.
Genomic DNA was isolated using a QIAamp DNA mini kit (Qiagen Nordic, Finland) and quantified on the NanoDrop spectrophotometer (NanoDrop Technologies, USA). As a reference we used DNA from pooled peripheral blood leukocytes of normal males. We screened for copy number alterations in five tumours using the Agilent Human 244K array format containing~240,000 oligonucleotide probes, covering both coding and noncoding genome regions (Agilent Technologies, USA). Briefly, 1.5 mg of tumour and reference DNA were digested, labelled and hybridised according to the Agilent protocols. The array images obtained after scanning (Agilent scanner G2565BA) were processed with Feature Extraction software (version 10.5), and the output data files were analysed with the Agilent Genomic Workbench. To identify copy number alterations we used the aberration detection method 2 (ADM-2) algorithm. To exclude small variances in the data we set up a custom aberration filter identifying alterations in copy number if a minimum of eight probes gained or lost were identified, with a minimum absolute average log ratio for the region being 0.5. Regions with small copy number variations were excluded by comparing and visualising the copy number variant regions of the Genomic Workbench software tool.
Fluorescence in situ hybridisation (FISH)
FISH analysis was performed using a centromeric-specific probe for the chromosome 3 centromere (SpectrumGreen CEP3; Abbott, Italy) and a subtelomeric probe for 3p25 (SpectrumGreen 3p-LSI; Abbott) in order to evaluate 3p deletion. Centromeric-specific probes for the chromosome 7 and 17 centromere were also used (SpectrumGreen, SpectrumOrange; Abbott).
From the whole-tissue sections, 3 mm sections were cut from paraffinembedded blocks. The paraffin was removed from the sections with two 10 min washes with xylene. After hydrating in 100%, 85%, and 70% ethanol solutions (10 min), rinsing in distilled water (10 min), and twice in phosphatebuffered solution (pH 7, 10 min each), the slides were fixed in methanol-acetic acid 3:1 for 10 min and air-dried. Next, the sections were treated in a 2X standard saline citrate solution for 15 min at 37 C, dehydrated in consecutive 70%, 85%, and 100% ethanol solution for 1 min each and then dried. Next, the sections were bathed in 0.1 mM citric acid (pH 6) solution at 85 C for 1 h. They were then dehydrated in a series of ethanol solutions and dried. The tissue was digested by applying 0.75 mL of pepsin (Sigma, USA) solution (4 mg/mL in 0.9% NaCl, pH 1.5) to each slide and incubating in a humidified box for 30 min at 37 C. Next, the slides were rinsed with distilled water for a few seconds, dehydrated in graded ethanol solutions, and dried. Centromeric probes for chromosomes 3 and the locus specific sub-telomeric probe 3p were used. Each probe was diluted 1:20 in t-DenHyb-2 buffer (LiStar-FISH, Italy). 15, 16 Ten mL of diluted probe was applied to each slide and cover slips were placed over the slides. Denaturation was achieved by incubating the slides at 80 C for 10 min in a humidified box, and then hybridisation was carried out at 37 C for 16 h. The cover slips were later removed and the slides were immersed at room temperature in 0.5X SSC for 2 min, in 50% formamide/1X SSC for 5 min, and in 2X SSC for 2 min. The slides were air-dried and counterstained with 10 mL DAPI/Antifade (DAPI in Fluorguard, 0.5 mg/ ml; Insitus, USA). The slides were examined using an Olympus BIX-61 microscope (Olympus, Germany) with filters for SpectrumGreen, and the UV Filter for the DAPI nuclear counterstain. The signals were recorded with a Genomic DNA was isolated from three 5 mM thick paraffin sections of each renal carcinoma sample using the Ex-Wax DNA Extraction Kit (Chemicon International, USA) according to the manufacturer's instructions. Bidirectional sequencing of PCR products was performed using an ABI Prism BigDye terminators v3.1 cycle sequencing kit (Applied Biosystems), and sequences were run on an Applied Biosystems 3130 Genetic Analyzer and compared with the reference sequence CCDS 2597.1. The PCR amplicon carrying the mutation was subcloned into a pGEM-T Easy vector (Promega, USA), transformed in competent DH5a cells and plated onto LB agar with ampicillin and X-gal selection. Then, 12 distinct blank (white) colonies were chosen, plasmid DNA was extracted and submitted for amplification and sequencing of VHL exon 3 as described above.
Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) and CpG methylation analysis
Microdissection of tissues from the five FFPE kidney tumours was performed manually. Genomic DNA extracted from the three samples was subjected to MS-MLPA using ME001-0808-C1 and ME002-0809-B1 probemixes (MRCHolland, The Netherlands) with 20-100 ng of DNA per sample. The standard MS-MLPA-protocol was employed. 20 Both probemixes contained one specific MLPA probe for the exon 1 of VHL gene that has a recognition site for a CpG methylation-sensitive endonuclease HhaI. The MS-MLPA product fragments were analysed by an ABI model 3130 capillary sequencer (Applied Biosystems, The Netherlands) using Genescan-ROX 500 size standards. As the same probemixes are intended to detect both copy number and methylation changes of the target genes simultaneously, both methylation and copy number status was analysed using Coffalyser software (MRC-Holland). The data were first normalised by dividing the peak area of a single probe by a cumulative peak area of all control probes (not degraded by HhaI). Then, the normalised peaks from the HhaI digestion reaction were compared to the normalised peaks from the undigested control reaction. Final methylation value for each sample was obtained by subtracting the background methylation values of the control samples (male and female DNA samples; Promega). The following criteria were used for determining the methylation status: 0.00-0.25 (absent), 0.25-0.50 (mild), 0.50-0.75 (moderate), and >0.75 (extensive methylation). For copy number analysis the following cut-off values were used: <0.7 and >1.3 gain. One DNA sample (labelled 8656) was excluded from the analysis due to the low amount of DNA and for another sample (labelled 10684) we were able to include only results using ME002-0809-B1 probemix as no DNA was available for the further analysis using the ME-001-0808 mix.
TCEB1 mutation analysis
TCEB1 gene Y79 and A100 hotspots were analysed by Sanger sequencing (Cases 1-5). PCR products were purified using Agencourt AMPure XP magnetic beads (Beckman Coulter, USA) and labelled with Big Dye Terminator v3.1 (Applied Biosystems, Italy). Agencourt CleanSEQ magnetic beads (Beckman Coulter) were used for post-labelling DNA fragment purification, and sequence analysis was performed on an Applied Biosystems 3130xl Genetic Analyzer.
RESULTS
Clinical and pathological findings
The patients were nine males and five females, with a mean age of 61 years (range 46-77 years). All tumours were well circumscribed, with a mean diameter of 2.4 cm (range 1.2-4.0 cm). All cases were pT1a. The clinical and pathological data of the cases are summarised in Table 1 . Macroscopically, one tumour (Case 5) exhibited a predominantly solid and greyish appearance, while the other 13 showed a variable cystic and solid morphology ( Fig. 1  and 2 ). No necrotic foci were seen. One tumour (Case 3) was yellow with a solid-microcystic appearance reminiscent of a conventional clear cell RCC. Microscopically, tumours showed encapsulation with differing architectural patterns as summarised in Table 2 . The papillary pattern was unique in that it occurred secondarily within enlarged tubules and cysts. Other architectural patterns were also present. These consisted of branching tubules similar to benign prostatic acini, and tubulo-glandular structures of variable sizes and shape, sometimes with ill-formed lumina imparting a solid appearance. Variable sized cysts were also seen, predominantly at the periphery of the tumour. All tumour cells had clear cytoplasm with nuclei aligned circumferentially, resembling secretory endometrium ( Fig. 2E-H) . The nuclei of all cases were predominantly low grade (ISUP nucleolar grade 1 or 2) (Fig. 3A-D) . The stroma was hyalinised although occasionally fibroleiomyomatous areas were also seen. Necrosis, mitotic activity, vascular invasion, or sarcomatoid change was not observed in any case.
Immunohistochemical findings
Immunohistochemical findings are summarised in Table 3 and Fig. 3 . Half of the cases were positive for CD10, ranging from 5% to 70% of neoplastic cells, and there was diffuse positivity for CK7 in 70-100% of cells. CK AE1-AE3 expression was seen in 100% of the neoplastic cells in all cases. SLC2A1 (GLUT1) and CAIX displayed variable intensity of expression in all, and in all but one case, respectively (one case not available for CAIX). Cytokeratin 34bE12 and CK14 showed an equivalent pattern of staining as they were expressed in the same 12 cases (12/14, 86%); Cases 3 and 6 were completely negative for both markers ( Fig. 3E-H ). CK1 and CK10 were constantly negative while CK5 showed positivity in four cases (percentages variable from 10 to 80%). Alpha-methylacyl-CoA racemase (P504S), HMB-45, cathepsin k, and oestrogen and progesterone receptors were constantly negative. S100A1 was expressed in nine of 13 cases (one case was not available), while parvalbumin showed weak immunoreactivity in 20% and 10% of the neoplasic cells in Cases 10 and 13, respectively. The stroma of the tumours showed focal positivity for alpha-smooth muscle actin in 12 of 14 cases, whereas there was complete negativity in the remaining two tumours. Only two of 150 clear cell RCC cases (1%) of the TMAs stained weakly positive for 34bE12 and CK14. We previously stained the same 150 conventional clear cell RCCs for CK7 and found it positive in 36 of 150 (24%) of the cases.
Western blot results
Two cases (Cases 2 and 4) revealed the appropriate positive band referring to CK14, respectively positive at immunohistochemistry in 60% and 40% of neoplastic cells. One case (Case 3) did not express the protein band, and was negative at immunohistochemistry. One case (Case 5) did not show evidence of the protein band but expression was observed in up to 40% of neoplastic cells at immunohistochemistry. The remaining two cases showed faint protein bands (Cases 10 and 14). Eight of 10 conventional clear cell RCCs were negative and two tumours showed a weak positive band.
aCGH results
We did not observe any gene copy number alterations in four of five cases analysed. DNA copy number changes were found in one tumour (Case 3) that showed deletions in chromosomes 3 (3p26.3q23, 3q25.1q25.2 and 3q25.32q26.2) and 6 (6q15q27) (Fig. 4, Table 4 ).
FISH findings
We analysed five cases by FISH.
Locus specific sub-telomeric 3p probe
Single, double and three or more fluorescent signals, respectively, were shown in neoplastic epithelial nuclei as follows: Case 1, 33%, 58% and 9%; Case 2, 34%, 61% and 5%; Case 3, 31%, 65% and 3%; Case 4, 35%, 59% and 6%; Case 5, 39%, 55% and 6%.
Centromeric chromosome 3 probe
Single, double and three or more fluorescent signals, respectively, were shown in neoplastic epithelial nuclei as follows: Case 1, 29%, 61% and 10%; Case 2, 35%, 62% and 3%; Case 3, 11%, 69% and 20%; Case 4, 44%, 53% and 9%; Case 5, 35%, 60% and 5%. 
VHL gene mutation
No mutation of coding sequence of the VHL gene was found in epithelial neoplastic components in four of five cases, 34bE12 FOR CLEAR CELL PAPILLARY RENAL CARCINOMA whereas one tumour (Case 3) showed a deletion in exon 1 (c.213del) ( Table 4) .
MLPA findings on methylation and copy number status of VHL MS-MLPA analysis of FFPE tissue DNA samples showed absent or mild methylation of VHL gene; the copy number of VHL gene was stable in all five analysed cases (Table 5 ).
TCEB1 gene mutation
No mutation of coding sequence of the TCEB1 gene was found in any tumour.
DISCUSSION
In this study we have demonstrated that: (1) the distinction between CCPRCC and low malignant potential multicystic RCC or conventional clear cell RCC, on the basis of morphological features, can be difficult; (2) the immunohistochemical expression of CK7 is necessary, but not sufficient to identify CCPRCC; (3) the immunoreactivity for 34bE12, in part due to the presence of CK14 in the neoplastic cells, can be extremely useful for identifying this tumour; (4) FISH can verify the presence of gains of chromosome 7 and 17 to differentiate CCPRCC from papillary RCC with clear cell changes, but it is not discriminatory when evaluating 3p status in differentiating this tumour from low malignant potential multicystic RCC or conventional clear cell RCC; (5) mutational analysis is the single most reliable method to differentiate rare CK7 positive conventional clear cell RCCs from CCPRCC; (6) the characteristic immunoprofile, including 34bE12 expression, and genomic signature, absence of 3p abnormalities, are observed in the entire morphological spectrum of CCPRCCs; (7) CCPRCC lacks highlighted that the papillary component is present only in 81% and 65% of cases, emphasising the branched tubular pattern, rather than the papillary pattern, as a distinctive morphological characteristic. This latter aspect, however, was often missing in tumours with a prominent cystic component. 3, 21 These data underscore the difficulties that may be encountered in distinguishing this tumour from papillary RCC with prominent clearing of cytoplasm, 21 34bE12 FOR CLEAR CELL PAPILLARY RENAL CARCINOMA was reclassified, while only three were originally interpreted as multilocular cystic RCCs. Recently, CCPRCC-like tumours have been described in patients with or without von Hippel-Lindau disease unrelated to sporadic CCPRCC, highlighting once again the difficulties that one might encounter in distinguishing CCPRCC from conventional clear cell RCC. 10 In support of the diagnostic difficulties mentioned above, one of the tumours (Case 3) that we selected as CCPRCC, based on morphological and immunophenotypical features (diffuse papillary architecture with a characteristic arrangement of the nuclei, as well as the presence of branched tubules and CK7 positivity), proved to be a conventional clear cell RCC with alterations of 3p identified by aCGH and VHL mutation. This tumour showed a strong and diffuse immunoreactivity for CK7 (70% of the neoplastic cells), a marker currently considered as extremely useful for differentiating CCPRCC from clear cell RCC. 2, 5 Although the majority of clear cell RCCs lack CK7 immunoexpression, some cases have been reported to be positive for this marker. We performed a literature search encompassing a total of 391 cases of clear cell RCC and found that 44 (12%) expressed CK7. [22] [23] [24] [25] Moreover, in our hands we have demonstrated this immunoreactivity in 24% of clear cell RCC. 
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As we demonstrated here, this might lead to misdiagnosis, even in the presence of morphological features typical of CCPRCC. 34bE12 is an antibody that recognises different high molecular weight cytokeratins including CK1, 5, 10 and 14; interestingly, we found 34bE12 to be positive in all but two cases (12/14) , one of these being the CK7 positive clear cell RCC case. Of note, only in 2011 was it initially reported that 34bE12 immunoexpression was observed in CCPRCC, and only recently Brimo et al. 27 and Aron et al. 12 reported additional CCPRCC with such positivity (Table 6 ). Aron et al. showed 41 of 42 cases with immunoexpression of 34bE12. 12 Rohan et al. showed seven of nine (78%) of their CCPRCC cases to be positive for this marker; on the other hand, 34bE12 immunostain was not detected in any of their clear cell RCC tested (0/11). 5 In our control group accounting for 150 clear cell RCCs, only two cases (1%) showed positivity for this marker. In order to better understand which specific cytokeratin is most responsible for the observed 34bE12 positivity in CCPRCC, we evaluated the immunoexpression of CK1, CK5, CK10 and CK14 separately. We found that, among these molecules, CK14 followed by CK5 are the most highly immunoexpressed high molecular weight cytokeratins in CCPRCC; these results are more likely to be verified by western blot analysis rather than immunohistochemical analysis. We also evaluated the expression of CK14
in TMAs containing 150 cases of conventional clear cell RCC and only the two cases positive for 34bE12 expressed CK14. Therefore, we suggest that applying 34bE12 to the immunohistochemical panel for diagnosing CCPRCC might be useful for distinguishing the latter from conventional clear cell RCC. Although FISH analysis is an extremely valuable aid for discriminating the different RCC histotypes, this is not always the case for CCPRCC versus clear cell RCC. 5, 15 In fact, in the tumour that we reclassified as clear cell RCC, only aCGH and gene sequencing allowed us to detect chromosomal imbalances and VHL alteration. However, FISH analysis remains a precise tool for detection of chromosome 7 and 17 gains, thus permitting the distinction between CCPRCC and papillary RCC. Interestingly, after the reclassification of our Case 3 as clear cell RCC, we went back to the diagnostic report of this tumour where it was described as a solid and microcystic yellowish lesion typical of clear cell RCC, which was in contrast to the gross characteristics of the other tumours in our series. Finally, Hakimi et al.
14 have recently reported that at least part of the so called RCC with angioleiomyoma-like stroma 28, 29 which shows overlapping morphological and immunophenotypical features with CCPRCC, carries mutations in TCEB1, a gene that contributes to the VHL complex to ubiquitinate hypoxiainducible factor. We confirmed their data regarding the absence of TCEB1 mutations in CCPRCC. Distinguishing CCPRCC from clear cell RCC is important, since the former has yet to be reported as having a malignant potential in cases with extensive genetic studies. As we noted above, despite having often distinctive morphological and immunohistochemical characteristics, these two entities can show overlapping features in few cases, resulting in diagnostic errors. In this study we have demonstrated that CK7 positivity and FISH evaluation for 3p deletion, although Table 6 CK34bE12 immunoexpression in clear cell papillary renal cell carcinoma frequently useful, might not be sufficient for distinguishing CCPRCC from conventional clear cell RCC in a minority cohort. In view of this we propose the use of 34bE12 to improve diagnostic accuracy in this differential diagnosis. and VHL mutation analysis should be considered the gold standard to evaluate cases characterised by chromosome 3p deletion associated with both CK7 and 34bE12 expression.
